Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population

Genes (Basel). 2022 Oct 15;13(10):1867. doi: 10.3390/genes13101867.

Abstract

(1) Background: The purpose of this study was to evaluate the effect of gene polymorphisms on prothrombin time (PT) and activated partial thromboplastin time (APTT) in a healthy Chinese population. (2) Methods: A total of 403 healthy volunteers from a series of novel oral anticoagulants (NOACs) bioequivalence trials in China were included. Coagulation tests for PT and APTT were performed in the central lab at Peking University First Hospital. Whole-exome sequencing (WES) and genome-wide association analysis were performed. (3) Results: In the correlation analysis of PT, 105 SNPs from 84 genes reached the genome-wide significance threshold (p < 1 × 10−5). Zinc Finger Protein 594 (ZNF594) rs184838268 (p = 4.50 × 10−19) was most significantly related to PT, and Actinin Alpha 1 (ACTN1) was found to interact most with other candidate genes. Significant associations with previously reported candidate genes Aurora Kinase B (AURKB), Complement C5(C5), Clock Circadian Regulator (CLOCK), and Histone Deacetylase 9(HDAC9) were detected in our dataset (p < 1 × 10−5). PiggyBac Transposable Element Derived 2(PGBD2) rs75935520 (p = 4.49 × 10−6), Bromodomain Adjacent To Zinc Finger Domain 2A(BAZ2A) rs199970765 (p = 5.69 × 10−6) and Protogenin (PRTG) rs80064850 (p = 8.69 × 10−6) were significantly correlated with APTT (p < 1 × 10−5). The heritability values of PT and APTT were 0.83 and 0.64, respectively; (4) Conclusion: The PT and APTT of healthy populations are affected by genetic polymorphisms. ZNF594 and ACTN1 variants could be novel genetic markers of PT, while PRTG polymorphisms might be associated with APTT levels. The findings could be attributed to ethnic differences, and need further investigation.

Keywords: activated partial thromboplastin time (APTT); genome-wide association analysis; healthy population; prothrombin time (PT); whole-exome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actinin*
  • Administration, Oral
  • Anticoagulants
  • Aurora Kinase B
  • Blood Coagulation Tests
  • Chromosomal Proteins, Non-Histone
  • Complement C5
  • DNA Transposable Elements
  • Genetic Markers
  • Genome-Wide Association Study*
  • Histone Deacetylases
  • Humans
  • Partial Thromboplastin Time
  • Polymorphism, Genetic
  • Prothrombin Time

Substances

  • Actinin
  • Aurora Kinase B
  • Genetic Markers
  • DNA Transposable Elements
  • Anticoagulants
  • Complement C5
  • Histone Deacetylases
  • BAZ2A protein, human
  • Chromosomal Proteins, Non-Histone

Grants and funding

This research was supported by grants from the National Key R&D Program of China (2016YFC0904900), National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (2017ZX09101001), National Natural Science Foundation of China (82073935, 81973395, and 81872940), and Beijing Municipal Commission of Science and Technology of China Pharmaceutical Innovation Cultivation and Industry Support Platform Capacity Construction Project (Z191100007619038).